Nutex Health Inc Stock Price, News & Analysis

Nutex Health (NASDAQ: NUTX) will attend and present at the 2026 J.P. Morgan Healthcare Conference in San Francisco on January 12–15, 2026. Company executives attending include CEO Tom Vo, M.D., MBA, CFO Jon Bates, and President Warren Hosseinion. Nutex Health's presentation is scheduled for Wednesday, January 14, 2026 at 4:30 PM PST at The Westin St. Francis.

The company is a physician-led integrated healthcare delivery system operating 26 micro hospitals and hospital outpatient departments across 12 states, with primary care-centric risk-bearing physician networks.

Nutex Health (NASDAQ: NUTX) opened Archview ER & Hospital in St. Louis on December 22, 2025, marking its 26th hospital and its first location in Missouri.

The 16,000 sq ft facility at 1320 N. Jefferson Ave offers 15 emergency beds, 3 inpatient suites, a full-service laboratory and advanced imaging (MRI, CT, X-ray, ultrasound) with same-day scheduling, and 24/7/365 concierge-level care.

The site is positioned in North St. Louis with views of the Gateway Arch and proximity to the National Geospatial-Intelligence Agency campus.

Nutex Health (NASDAQ: NUTX) announced its Board has extended a previously authorized $25.0 million common stock repurchase program through March 31, 2026. The program, first authorized Aug 14, 2025, began upon filing the Form 10-Q for the quarter ended June 30, 2025 and will be executed under Rule 10b-18 and a Rule 10b5-1 trading plan scheduled to take effect on or about Dec 4, 2025. The company said the buyback aims to increase shareholder value and offset dilution from stock compensation for under-construction and ramping hospitals. Repurchases remain discretionary and may be affected by market, financial, legal and capital considerations.

Nutex Health (NASDAQ: NUTX) announced the reopening of Red River ER & Hospital in Sherman, Texas on November 24, 2025. The 18,500 sq ft facility offers 24/7/365 concierge-level care with seven ER beds, four inpatient suites, and two triage rooms. The site includes a full-service laboratory and advanced imaging (MRI, CT, X-ray, ultrasound) with same-day scheduling and rapid results.

Company leaders highlighted the hospital's role serving the growing Sherman area and nearby Oklahoma communities and emphasized upgraded equipment, reduced wait times, and around-the-clock clinical staffing.

Nutex Health (NASDAQ: NUTX) reported strong results for the three and nine months ended September 30, 2025, driven by the hospital division and arbitration recoveries. Nine‑month revenue was $723.6M, up 225.5% versus 2024, with hospital revenue of $700.5M (up 251.4%). Net income attributable to Nutex Health was $59.0M for nine months versus a $9.5M loss in 2024. EBITDA was $142.9M and Adjusted EBITDA was $243.0M for nine months. Cash and cash equivalents totaled $166.0M and net cash from operating activities was $177.7M for the nine months. The company noted substantial stock‑based compensation of $119.6M and significant reliance on IDR arbitration recoveries (≈66% of hospital revenue for nine months).

Nutex Health (NASDAQ: NUTX) reported strong first-half 2025 results: total revenue $455.8M versus $143.5M (+217.5%), net income attributable $3.5M vs a $0.7M loss, and diluted EPS $0.55. Adjusted EBITDA $144.4M (vs $6.4M), and EBITDA $51.1M. Cash balance was a record $96.7M and net cash from operations was $78.2M. Hospital division visits reached 93,842 (+15.5% YTD). The board authorized an opportunistic $25.0M share repurchase program on August 14, 2025. Total stock-based compensation was $106.4M for H1 2025, primarily for under-construction and ramping hospitals. Total assets were $841.0M as of June 30, 2025.

NUTEX HEALTH (NASDAQ: NUTX) reported restated Q1 2025 results for the quarter ended March 31, 2025, including a 214.0% increase in total revenue to $211.8M and net income attributable to Nutex of $21.2M versus a $0.4M loss in Q1 2024. EBITDA was $51.5M and Adjusted EBITDA was $72.8M. The company recorded $27.6M of stock-based compensation (≈99% related to under-construction and ramping hospitals).

The restatement corrected non-cash classifications (stock-based compensation reclassified from equity to liabilities, related-party payables reclassified to equity, $2.9M moved to short-term investments, and accrued income tax expense increased $2.4M). Total liabilities rose by $19.6M (4.0%), total equity declined $19.6M (7.1%), and net income for the period increased by $6.6M (14.9%) on the restated basis. Cash and cash equivalents were $84.7M and net cash from operating activities was $51.0M.

NUTEX HEALTH (NASDAQ: NUTX) reported restated full-year and Q4 2024 results on Nov 18, 2025 reflecting non-cash reclassifications and immaterial net-income impact.

Key 2024 metrics: total revenue $479.9M (+93.8% vs 2023); net income attributable $52.1M vs loss $45.8M in 2023; diluted EPS $9.69; EBITDA $98.8M; Adjusted EBITDA $124.1M. Q4 revenue $257.6M (+269.8% YoY); Q4 net income $61.6M.

Restatement adjustments reclassified $16.4M of stock‑based compensation to liabilities, moved $3.5M related‑party payables to equity, shifted $2.9M to short‑term investments, and increased accrued tax by $0.5M; total liabilities rose $13.4M (2.9%).